Inhibition of Stearoyl-coA Desaturase Selectively Eliminates Tumorigenic Nanog-positive Cells: Improving the Safety of IPS Cell Transplantation to Myocardium

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2014 Jan 8

PMID 24394703

Citations 21

Authors

Lan Zhang

Yaohua Pan

Gangjian Qin

Lijuan Chen

Tapan K Chatterjee

Neal L Weintraub

Yaoliang Tang

Affiliations

Soon will be listed here.

Abstract

Induced pluripotent stem cells (iPS) can differentiate into cardiomyocytes (CM) and represent a promising form of cellular therapy for heart regeneration. However, residual undifferentiated iPS derivates (iPSD), which are not fully eliminated by cell differentiation or purification protocols, may form tumors after transplantation, thus compromising therapeutic application. Inhibition of stearoyl-coA desaturase (SCD) has recently been reported to eliminate undifferentiated human embryonic stem cells, which share many features with iPSD. Here, we tested the effects of PluriSin#1, a small-molecule inhibitor of SCD, on iPS-derived CM. We found that plurisin#1 treatment significantly decreased the mRNA and protein level of Nanog, a marker for both cell pluripotency and tumor progression; importantly, we provide evidence that PluriSin#1 treatment at 20 µM for 1 day significantly induces the apoptosis of Nanog-positive iPSD. In addition, PluriSin#1 treatment at 20 µM for 4 days diminished Nanog-positive stem cells in cultured iPSD while not increasing apoptosis of iPS-derived CM. To investigate whether PluriSin#1 treatment prevents tumorigenicity of iPSD after cell transplantation, we intramyocardially injected PluriSin#1- or DMSO-treated iPSD in a mouse model of myocardial infarction (MI). DMSO-treated iPSD readily formed Nanog-expressing tumors 2 weeks after injection, which was prevented by treatment with PluriSin#1. Moreover, treatment with PluriSin#1 did not change the expression of cTnI, α-MHC, or MLC-2v, markers of cardiac differentiation (P>0.05, n = 4). Importantly, pluriSin#1-treated iPS-derived CM exhibited the ability to engraft and survive in the infarcted myocardium. We conclude that inhibition of SCD holds the potential to enhance the safety of therapeutic application of iPS cells for heart regeneration.

Citing Articles

Metabolic changes of human induced pluripotent stem cell-derived cardiomyocytes and teratomas after transplantation.

Soma Y, Tohyama S, Kubo A, Yamasaki T, Kabasawa N, Haga K iScience. 2024; 27(11):111234.

PMID: 39569381 PMC: 11576393. DOI: 10.1016/j.isci.2024.111234.

Recent advancements of human iPSC derived cardiomyocytes in drug screening and tissue regeneration.

Huang Y, Wang T, Lopez M, Hirano M, Hasan A, Shin S Microphysiol Syst. 2024; 4:2.

PMID: 39430371 PMC: 11488690. DOI: 10.21037/mps-20-3.

Assessing Tumorigenicity in Stem Cell-Derived Therapeutic Products: A Critical Step in Safeguarding Regenerative Medicine.

Wang Z Bioengineering (Basel). 2023; 10(7).

PMID: 37508884 PMC: 10376867. DOI: 10.3390/bioengineering10070857.

Glioblastoma Stem-Like Cells (GSCs) with Mesenchymal Signature: Lipid Profiles of Mobile Lipids Obtained with MRS before and after Radio/Chemical Treatments.

Grande S, Palma A, Luciani A, Anello P, Ricci-Vitiani L, Buccarelli M Biomolecules. 2022; 12(8).

PMID: 36008944 PMC: 9405836. DOI: 10.3390/biom12081051.

A small molecule modulating monounsaturated fatty acids and Wnt signaling confers maintenance to induced pluripotent stem cells against endodermal differentiation.

Hosseini V, Kalantary-Charvadeh A, Hajikarami M, Fayyazpour P, Rahbarghazi R, Totonchi M Stem Cell Res Ther. 2021; 12(1):550.

PMID: 34674740 PMC: 8532309. DOI: 10.1186/s13287-021-02617-x.

References

Okita K, Ichisaka T, Yamanaka S . Generation of germline-competent induced pluripotent stem cells. Nature. 2007; 448(7151):313-7. DOI: 10.1038/nature05934. View

Li W, Xiang A . Safeguarding clinical translation of pluripotent stem cells with suicide genes. Organogenesis. 2013; 9(1):34-9. PMC: 3674039. DOI: 10.4161/org.24317. View

Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K . Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol. 2009; 27(8):743-5. DOI: 10.1038/nbt.1554. View

Tang Y, Zhu W, Cheng M, Chen L, Zhang J, Sun T . Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res. 2009; 104(10):1209-16. PMC: 2756190. DOI: 10.1161/CIRCRESAHA.109.197723. View

Ben-David U, Gan Q, Golan-Lev T, Arora P, Yanuka O, Oren Y . Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell. 2013; 12(2):167-79. DOI: 10.1016/j.stem.2012.11.015. View

Suzuki A, Raya A, Kawakami Y, Morita M, Matsui T, Nakashima K . Nanog binds to Smad1 and blocks bone morphogenetic protein-induced differentiation of embryonic stem cells. Proc Natl Acad Sci U S A. 2006; 103(27):10294-10299. PMC: 1502451. DOI: 10.1073/pnas.0506945103. View

Song H, Song B, Cha M, Choi I, Hwang K . Modification of mesenchymal stem cells for cardiac regeneration. Expert Opin Biol Ther. 2010; 10(3):309-19. DOI: 10.1517/14712590903455997. View

Scaglia N, Igal R . Stearoyl-CoA desaturase is involved in the control of proliferation, anchorage-independent growth, and survival in human transformed cells. J Biol Chem. 2005; 280(27):25339-49. DOI: 10.1074/jbc.M501159200. View

Ohnuki M, Takahashi K, Yamanaka S . Generation and characterization of human induced pluripotent stem cells. Curr Protoc Stem Cell Biol. 2009; Chapter 4:Unit 4A.2. DOI: 10.1002/9780470151808.sc04a02s9. View

10.

Yang Y, Niu C, Cheng C . Pin1-Nanog expression in human glioma is correlated with advanced tumor progression. Oncol Rep. 2013; 30(2):560-6. PMC: 3776722. DOI: 10.3892/or.2013.2481. View

11.

Yang L, Zhang X, Zhang M, Zhang J, Sheng Y, Sun X . Increased Nanog expression promotes tumor development and Cisplatin resistance in human esophageal cancer cells. Cell Physiol Biochem. 2012; 30(4):943-52. DOI: 10.1159/000341471. View

12.

Lowry W . Does transcription factor induced pluripotency accurately mimic embryo derived pluripotency?. Curr Opin Genet Dev. 2012; 22(5):429-34. PMC: 3753773. DOI: 10.1016/j.gde.2012.07.003. View

13.

Narazaki G, Uosaki H, Teranishi M, Okita K, Kim B, Matsuoka S . Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation. 2008; 118(5):498-506. DOI: 10.1161/CIRCULATIONAHA.108.769562. View

14.

Ye L, Zhang S, Greder L, Dutton J, Keirstead S, Lepley M . Effective cardiac myocyte differentiation of human induced pluripotent stem cells requires VEGF. PLoS One. 2013; 8(1):e53764. PMC: 3542360. DOI: 10.1371/journal.pone.0053764. View

15.

Lim S, Sivakumaran P, Crombie D, Dusting G, Pebay A, Dilley R . Trichostatin A enhances differentiation of human induced pluripotent stem cells to cardiogenic cells for cardiac tissue engineering. Stem Cells Transl Med. 2013; 2(9):715-25. PMC: 3754471. DOI: 10.5966/sctm.2012-0161. View

16.

Zwi L, Caspi O, Arbel G, Huber I, Gepstein A, Park I . Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation. 2009; 120(15):1513-23. DOI: 10.1161/CIRCULATIONAHA.109.868885. View

17.

Mummery C, Zhang J, Ng E, Elliott D, Elefanty A, Kamp T . Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res. 2012; 111(3):344-58. PMC: 3578601. DOI: 10.1161/CIRCRESAHA.110.227512. View

18.

Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View

19.

Menendez S, Camus S, Herreria A, Paramonov I, Morera L, Collado M . Increased dosage of tumor suppressors limits the tumorigenicity of iPS cells without affecting their pluripotency. Aging Cell. 2011; 11(1):41-50. DOI: 10.1111/j.1474-9726.2011.00754.x. View

20.

Santagata S, Ligon K, Hornick J . Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol. 2007; 31(6):836-45. DOI: 10.1097/PAS.0b013e31802e708a. View